Form 4: Stoke Therapeutics GC Sells Shares for Tax Obligations

Stoke Therapeutics' General Counsel, Jonathan Allan, reported the sale of 8,895 common shares to cover tax withholding liabilities from restricted stock unit vesting.

Summary

• Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported multiple sales of common stock.
• A total of 8,895 shares were sold across several transactions on March 17 and March 18, 2026.
• The sales were issuer-mandated to satisfy tax withholding liabilities associated with the vesting and settlement of restricted stock units.
• The transactions were executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.
• Following these transactions, Jonathan Allan beneficially owns 28,836 shares of Stoke Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The reported sales are routine, non-discretionary transactions by an executive to cover tax obligations related to equity compensation, not a reflection of a change in company outlook.

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax withholding liabilities upon the vesting of restricted stock units are a standard and common practice in corporate compensation. These transactions are typically pre-scheduled under Rule 10b5-1 plans and are generally not indicative of an insider's discretionary view on the company's future performance or a broader industry trend.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, non-discretionary sales for tax purposes and do not signal a change in company fundamentals or insider confidence.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by an executive to cover tax obligations related to restricted stock unit vesting. Such transactions are common and do not typically signal a change in the company's fundamentals or management's confidence. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Transaction, Share Sale, Tax Withholding, Restricted Stock Units, Jonathan Allan